Tirzepatide Buffer Composition for Stability and Low Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of tirzepatide, a dual GIP/GLP-1 receptor agonist, face challenges such as chemical instability, aggregation, and immunogenicity due to inorganic buffers like sodium phosphate, which also cause injection site irritation and require stringent storage conditions, leading to increased manufacturing costs and greenhouse gas emissions.
Innovation Solution
A pharmaceutical composition using non-inorganic buffers with a pKa of 6.6 to 8.6, such as zwitterionic or organic amine-based buffers, maintains a pH between 6.5 to 8.5, reducing impurities and fibril formation, and is prepared at lower temperatures to enhance stability and reduce energy consumption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If inorganic buffers like sodium phosphate are used in tirzepatide formulations, then pH control is effective, but chemical instability, aggregation, and immunogenicity increase
Solution Approach 1:
The patent changes the chemical composition parameter by replacing inorganic buffers with organic buffer systems (citrate, acetate, lactate, or amino acid buffers) that have different chemical properties. This substitution modifies the chemical environment to reduce peptide aggregation and immunogenicity while maintaining pH control, directly addressing the stability-harmful factors contradiction.
Solution Approach 2:
The patent introduces specific organic buffer compounds as intermediary substances between the peptide and the formulation environment. These organic buffers act as mediators that prevent direct harmful interactions while maintaining pH control, reducing aggregation and immunogenicity without sacrificing stability.
2Reliability
If inorganic buffers are used to maintain pH control, then therapeutic efficacy is maintained, but injection site irritation increases
Solution Approach 1:
The patent changes the buffer composition from inorganic to organic systems, which alters the physiological interaction with tissue. Organic buffers like citrate, acetate, and amino acid buffers have different ionic and chemical properties that reduce local tissue irritation while maintaining the pH necessary for therapeutic efficacy.
3Stability of the object's composition
If inorganic buffers are used in the formulation, then pH control is achieved, but crystallization and precipitate formation occur under storage conditions
Solution Approach 1:
The patent changes the buffer chemistry from inorganic to organic systems with different solubility and crystallization characteristics. Organic buffers generally have higher solubility and lower tendency to form crystalline precipitates under varying storage temperatures and pH conditions, thereby improving storage stability while maintaining pH control.
4Duration of action of stationary object
If heating treatment is applied to reduce fibril formation, then shelf life increases, but manufacturing energy consumption increases
Solution Approach 1:
The patent extracts and eliminates the need for high-temperature heating treatment by using organic buffer systems that inherently prevent fibril formation. This approach achieves extended shelf life through formulation chemistry rather than thermal processing, thereby reducing manufacturing energy consumption while maintaining or improving stability.
Solution Approach 2:
The patent changes the formulation parameters by using organic buffers that shift the aggregation behavior of the peptide, preventing fibril formation at lower temperatures. This chemical parameter change allows for extended shelf life without requiring energy-intensive heating processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves improved stability, reduced impurity content, and lower fibril formation, allowing for room temperature storage and energy-efficient manufacturing, while maintaining therapeutic efficacy.
Implementation Method 1
at least one non-inorganic buffer having a pKa of at least 6.6 or above (e.g., a pKa of about 6.6 to about 8.6)
Data Source
AI summary
Disclosed herein is a stable pharmaceutical composition comprising a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist (e.g., tirzepatide). Also disclosed herein is an aqueous composition comprising tirzepatide and at least one non-inorganic buffer; formulated for enhanced storage stability and reduced aggregation, ensuring optimal therapeutic efficacy in the treatment of diabetes mellitus and obesity.